Cargando…
Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is caused by the autoimmune targeting of pancreatic β-cells, and, in the advanced stage, severe hypoinsulinemia due to islet destruction. In patients with T1DM, continuous exogenous insulin therapy cannot be avoided. However, an insufficient dose of insulin easily ind...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406504/ https://www.ncbi.nlm.nih.gov/pubmed/30781427 http://dx.doi.org/10.3390/jcm8020249 |
_version_ | 1783401320349171712 |
---|---|
author | Takahashi, Hiroyuki Sakata, Naoaki Yoshimatsu, Gumpei Hasegawa, Suguru Kodama, Shohta |
author_facet | Takahashi, Hiroyuki Sakata, Naoaki Yoshimatsu, Gumpei Hasegawa, Suguru Kodama, Shohta |
author_sort | Takahashi, Hiroyuki |
collection | PubMed |
description | Type 1 diabetes mellitus (T1DM) is caused by the autoimmune targeting of pancreatic β-cells, and, in the advanced stage, severe hypoinsulinemia due to islet destruction. In patients with T1DM, continuous exogenous insulin therapy cannot be avoided. However, an insufficient dose of insulin easily induces extreme hyperglycemia or diabetic ketoacidosis, and intensive insulin therapy may cause hypoglycemic symptoms including hypoglycemic shock. While these insulin therapies are efficacious in most patients, some additional therapies are warranted to support the control of blood glucose levels and reduce the risk of hypoglycemia in patients who respond poorly despite receiving appropriate treatment. There has been a recent gain in the popularity of cellular therapies using mesenchymal stromal cells (MSCs) in various clinical fields, owing to their multipotentiality, capacity for self-renewal, and regenerative and immunomodulatory potential. In particular, adipose tissue-derived MSCs (ADMSCs) have become a focus in the clinical setting due to the abundance and easy isolation of these cells. In this review, we outline the possible therapeutic benefits of ADMSC for the treatment of T1DM. |
format | Online Article Text |
id | pubmed-6406504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64065042019-03-22 Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus Takahashi, Hiroyuki Sakata, Naoaki Yoshimatsu, Gumpei Hasegawa, Suguru Kodama, Shohta J Clin Med Review Type 1 diabetes mellitus (T1DM) is caused by the autoimmune targeting of pancreatic β-cells, and, in the advanced stage, severe hypoinsulinemia due to islet destruction. In patients with T1DM, continuous exogenous insulin therapy cannot be avoided. However, an insufficient dose of insulin easily induces extreme hyperglycemia or diabetic ketoacidosis, and intensive insulin therapy may cause hypoglycemic symptoms including hypoglycemic shock. While these insulin therapies are efficacious in most patients, some additional therapies are warranted to support the control of blood glucose levels and reduce the risk of hypoglycemia in patients who respond poorly despite receiving appropriate treatment. There has been a recent gain in the popularity of cellular therapies using mesenchymal stromal cells (MSCs) in various clinical fields, owing to their multipotentiality, capacity for self-renewal, and regenerative and immunomodulatory potential. In particular, adipose tissue-derived MSCs (ADMSCs) have become a focus in the clinical setting due to the abundance and easy isolation of these cells. In this review, we outline the possible therapeutic benefits of ADMSC for the treatment of T1DM. MDPI 2019-02-15 /pmc/articles/PMC6406504/ /pubmed/30781427 http://dx.doi.org/10.3390/jcm8020249 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Takahashi, Hiroyuki Sakata, Naoaki Yoshimatsu, Gumpei Hasegawa, Suguru Kodama, Shohta Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus |
title | Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus |
title_full | Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus |
title_fullStr | Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus |
title_full_unstemmed | Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus |
title_short | Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus |
title_sort | regenerative and transplantation medicine: cellular therapy using adipose tissue-derived mesenchymal stromal cells for type 1 diabetes mellitus |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406504/ https://www.ncbi.nlm.nih.gov/pubmed/30781427 http://dx.doi.org/10.3390/jcm8020249 |
work_keys_str_mv | AT takahashihiroyuki regenerativeandtransplantationmedicinecellulartherapyusingadiposetissuederivedmesenchymalstromalcellsfortype1diabetesmellitus AT sakatanaoaki regenerativeandtransplantationmedicinecellulartherapyusingadiposetissuederivedmesenchymalstromalcellsfortype1diabetesmellitus AT yoshimatsugumpei regenerativeandtransplantationmedicinecellulartherapyusingadiposetissuederivedmesenchymalstromalcellsfortype1diabetesmellitus AT hasegawasuguru regenerativeandtransplantationmedicinecellulartherapyusingadiposetissuederivedmesenchymalstromalcellsfortype1diabetesmellitus AT kodamashohta regenerativeandtransplantationmedicinecellulartherapyusingadiposetissuederivedmesenchymalstromalcellsfortype1diabetesmellitus |